Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | CASSIOPEIA: D-VTD in high-risk multiple myeloma

Aurore Perrot • 31 Aug 2020
EBMT 2020
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Thalidomide
CASSIOPEIA

Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the CASSIOPEIA study (NCT02541383) evaluating the use of daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in autologous transplant-eligible newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Aurore Perrot

The role of transplant in myeloma
0:48
The role of transplant in myeloma
Aurore Perrot • 9 Sep 2021
Real-world data: treatment pathways for myeloma patients in France
2:23
Real-world data: treatment pathways for myeloma patients in France
Aurore Perrot • 9 Sep 2021
Moving towards a cure for myeloma
0:40
Moving towards a cure for myeloma
Aurore Perrot • 9 Sep 2021
IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma
5:24
IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma
Aurore Perrot • 7 Dec 2020

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Aurore Perrot • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Aurore Perrot • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Aurore Perrot • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Aurore Perrot • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals